Zebrafish Study: Rare Disease Drug Candidates Identified
- Researchers at the University of Alabama at Birmingham (UAB) and the Hospital for Sick Children have identified two drugs, edaravone and LY294002, that show promise in treating X-linked...
- The team used a zebrafish model to study XMEA, which in humans presents with varying degrees of muscle weakness.
- As the fish displayed impaired autophagy, and given the lack of existing therapies for XMEA patients, the researchers screened 30 autophagy inhibitory compounds on the XMEA zebrafish.
Researchers have pinpointed potential drug candidates for X-linked myopathy with excessive autophagy (XMEA), a rare genetic disorder, using a zebrafish model. Their pivotal study identified edaravone and LY294002 as promising treatments, offering hope where few options existed. The team’s examination, detailed in the latest research, used zebrafish to mimic XMEA symptoms, revealing that these compounds considerably improved survival rates and motor function. The study screened numerous autophagy inhibitory compounds, sourced from the selleckchem drug library, underlining the critical role of autophagy modulation in addressing this debilitating condition. News Directory 3 brings you the latest on these breakthroughs. With encouraging results, the team is moving closer to preparing for clinical trials. Discover what’s next in the quest to treat XMEA and improve lives with new, targeted therapies.
Zebrafish Model Reveals Potential Drugs for Rare Genetic Disease
Researchers at the University of Alabama at Birmingham (UAB) and the Hospital for Sick Children have identified two drugs, edaravone and LY294002, that show promise in treating X-linked myopathy with excessive autophagy (XMEA), a rare genetic disorder.
The team used a zebrafish model to study XMEA, which in humans presents with varying degrees of muscle weakness. The zebrafish, however, exhibited a more severe form of the disease, resulting in a considerably reduced life span. This is likely due to a more complete loss of VMA function compared to human patients.
As the fish displayed impaired autophagy, and given the lack of existing therapies for XMEA patients, the researchers screened 30 autophagy inhibitory compounds on the XMEA zebrafish. The compounds were sourced from the selleckchem drug library.
The screening process involved observing changes in muscle birefringence, an indicator of muscle organization. Nine compounds were found to both reduce abnormal birefringence and extend the survival of the fish. Further testing narrowed the field to edaravone and LY294002, which demonstrated the most significant therapeutic effects on survival and swimming ability.
According to Dr. Alexander, a researcher involved in the study, several autophagy antagonists improved aspects of the zebrafish phenotype. He added that edaravone and LY294002, in particular, improved the phenotype across multiple domains of birefringence, motor function and survival. He said the fact that multiple autophagy modulators ameliorated aspects of the phenotype supports an important role for autophagy in the disease process and lends confidence to the validity and potential translatability of the findings to patients.
What’s next
The researchers plan to continue investigating the mechanisms by which edaravone and LY294002 improve XMEA symptoms in preparation for potential clinical trials.